Media Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb…
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar…
Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive…
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIESANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to…
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg PharmaPoolbeg team boosted by highly experienced executives with track…
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment…
Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous…
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…
Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent…
Neuropilin-1 (NRP1), implicated in various pro-tumorigenic processes, is a promising therapeutic target for cancer treatmentSecarna designed LNA-modified NRP1 specific antisense…